12 citations
,
May 2016 in “British Journal of Dermatology” This report describes a rare case of epidermolysis bullosa acquisita in a child developing during therapy with squaric acid dibutyl ester for alopecia areata, suggesting a possible link between the medication and disease onset.
July 2024 in “Journal of Investigative Dermatology” This study suggests that macrophages, especially CD206+ subsets, play a key role in hair growth induced by squaric acid dibutyl ester, a therapy used for alopecia areata.
42 citations
,
August 1987 in “Archives of Dermatology” In this study, 28.5% of patients with extensive alopecia areata had complete hair regrowth during treatment with squaric acid dibutylester, with outcomes linked to shorter alopecia duration and prompt dermatitis development.
21 citations
,
December 2014 in “Clinics in dermatology” This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.
15 citations
,
March 2008 in “The Journal of Dermatology” In this case report, a patient with a history of discoid lupus erythematosus experienced an exacerbation of the condition after topical immunotherapy for alopecia areata, suggesting contact dermatitis as a potential trigger.